Gabapentin use and a claim for memory loss in South Dakota

South Dakota's sparse population of 900,000 and vast rural geography create healthcare access challenges that drive pharmaceutical pain management reliance. The state's agricultural economy produces chronic pain from decades of physical labor, while limited specialist resources outside Sioux Falls and Rapid City mean gabapentin-induced cognitive decline is unlikely to be detected through routine care. South Dakota has not scheduled gabapentin as a controlled substance. The state's Native American population on reservations faces compounded healthcare access challenges and elevated chronic pain rates, creating a concentrated at-risk population for gabapentin cognitive effects.

For the overall process and updates, read the Gabapentin use and a claim for memory loss overview. This page covers the local information available for South Dakota.